MAP1A / Microtubule-associated protein 1A · IHC design guide

Design Immunohistochemistry for MAP1A

Plan chromogenic MAP1A IHC in paraffin sections using cerebellum or cerebral cortex as positive tissue (HPA tissue IHC). This guide covers cytoplasmic neuronal staining (HPA tissue IHC) and how MAP1A processing affects epitope selection (UniProt).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for MAP1A (IHC for MAP1A): expected localisation Cytoplasmic tissue staining (HPA tissue IHC), antibody A03897, validated IHC image, and IHC protocol steps — Printable **MAP1A** IHC protocol sheet — expected localisation Cytoplasmic tissue staining (HPA tissue IHC), antibody A03897, controls and protocol steps. Open the full MAP1A IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

MAP1A Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic tissue staining (HPA tissue IHC)
	Staining pattern	Cytoplasm of neurons, Purkinje cells and molecular-layer subsets (HPA tissue IHC)
	Antigen retrieval	Tris-EDTA pH 9.0 HIER, heat-mediated (datasheet A03897)
	Positive control ⓘ	Cerebellum+4 more · see all
	Negative control ⓘ	Adipose tissue+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across sections. (standard IHC practice; not target-specific)
	Caveat	Ciliated cells also stain in bronchus and nasopharynx (HPA tissue IHC)
	Regulation	Brain-enriched expression (UniProt)
	Isoform / epitope	2 isoforms; heavy-chain and LC2 processing makes epitope location relevant (UniProt)

Section 1

Recommended MAP1A IHC & IF Protocols

The catalog antibody IHC-P protocol (datasheet: A03897) is accompanied by one published prostate tissue microarray protocol (PMC4599305).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded human Colon cancer tissue; fixative not specified (datasheet A03897)
Fixation	Image fixative and duration unreported (datasheet A03897); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: Tris-EDTA pH 9.0 (datasheet A03897); 20 min, 95–100 °C (standard)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% normal serum of the secondary host, 30 min, room temperature (standard)
Primary antibody	Rabbit anti-MAP1A, 1:50 recommended; image 1:200 (datasheet A03897)
Primary incubation	Overnight at 4 °C (standard)
Detection	HRP-polymer secondary, DAB chromogen 5–10 min (standard)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	MAP1A-positive staining in gLUC cells - cytoplasm/membrane of cerebellum (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression most abundant in neuronal cells, Purkinje cells and subset of cells in molecular layer of cerebellum. No signal in the no-primary control.

💡Decision noteStart with Tris-EDTA pH 9.0 heat retrieval for the catalog antibody (datasheet: A03897); the published protocol used 10 mM citrate pH 6.0 (PMC4599305).

Section 2

What Is the Expected MAP1A Staining Pattern?

MAP1A is a cytoplasmic cytoskeletal protein without a transmembrane segment (UniProt P78559 topology). In paraffin section IHC, expect staining chiefly in neuronal cells, including cerebellar Purkinje cells and a subset of cells in the molecular layer (HPA tissue IHC: Enhanced reliability). Cerebral cortex neuronal staining is high, while hippocampal neuronal staining is medium (HPA tissue IHC). Interpret intensity within the identified cell type and tissue.

What am I looking at on my slide?
Neuronal cell bodies show cytoplasmic chromogen in cerebral cortex; cerebellar Purkinje cells and some molecular layer cells stain.	This fits the reported brain enriched pattern (HPA tissue IHC). Cerebral cortex neuronal staining is high; the cerebellar profile identifies Purkinje cells and a subset of molecular layer cells (HPA tissue IHC). Assess the stained cells against their local tissue context.
Predominantly nuclear signal appears in otherwise identifiable neuronal cells.	A nuclear dominant pattern does not fit the reported cytoplasmic cytoskeletal location (UniProt P78559 subcellular location; HPA tissue IHC). Treat it as suspect staining and compare it with an appropriate control and the expected cytoplasmic pattern (general IHC practice).
Strong staining appears broadly in adipocytes or bone marrow hematopoietic cells.	Those cell types are reported as not detected (HPA tissue IHC). Consider antibody cross reactivity or endogenous detection activity; an unexpected positive result alone cannot distinguish them (general IHC practice). Compare a no primary antibody control with a known positive section.
Chromogen is spread across cells and surrounding tissue, obscuring cell boundaries.	This is difficult to score as MAP1A because the reported tissue pattern identifies particular cells and cytoplasmic staining (HPA tissue IHC). Review blocking, antibody concentration, washes and detection controls as general IHC background checks (general IHC practice).
No neuronal cytoplasmic signal appears in a cerebral cortex section expected to be positive.	That conflicts with high neuronal staining reported in cerebral cortex (HPA tissue IHC). Check that the expected cells are present, then review the IHC assay and its controls; a single negative section cannot establish absent MAP1A expression (general IHC practice).

💡Expected MAP1A appearanceCall positive staining when identifiable neuronal cells show predominantly cytoplasmic signal, strongest in the reported high staining cerebral cortex pattern; isolated nuclear or broad cell type independent chromogen is suspect (HPA tissue IHC; UniProt P78559 subcellular location; general IHC practice).

How each factor affects the staining
Tissue and cell context	Brain is tissue enriched, but reported staining is not exclusive to neurons: ciliated bronchial and nasopharyngeal cells and small intestine endocrine cells show medium staining (HPA tissue IHC). Do not call every extra neural positive an artefact.
Intracellular location	MAP1A is cytoplasmic and cytoskeletal, with no transmembrane segment (UniProt P78559 topology). HPA also annotates cerebellar GLUC cells as cytoplasm/membrane, so a membrane associated appearance there needs cell context before rejection (HPA tissue IHC).
Processing and antibody recognition	The precursor yields a MAP1A heavy chain and LC2 light chain; two isoforms are listed (UniProt P78559 processing, isoforms). The supplied evidence gives no antibody epitope, so it cannot establish which processed form or isoform produces a given stain.
IHC evidence	The tissue profile has Enhanced reliability for consistency between antibody staining and RNA expression (HPA tissue IHC). HPA039063 and HPA039064 have Enhanced IHC status (HPA antibodies); this supports the reported pattern, without validating every unexpected cell or compartment.
IF/ICC: what localisation should I expect?	Mainly cytosolic signal is approved; additional mid piece and principal piece localisation is reported (HPA subcellular ICC-IF). Those IF observations provide a localisation check, while the tissue and intensity calls on this page come from paraffin section IHC (HPA tissue IHC).

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Cerebral cortex neurons have no visible stain.	High neuronal staining is expected there (HPA tissue IHC); an absent signal may reflect an IHC run or specimen issue (general IHC practice).	Confirm neuronal cells are present and review the positive control, antibody dilution, retrieval and detection steps used for this run (general IHC practice).
Signal is mainly nuclear.	Nuclear dominance conflicts with the reported cytoplasmic location (UniProt P78559 subcellular location; HPA tissue IHC).	Check the no primary antibody control and compare cytoplasmic signal in a known positive neuronal section before scoring (general IHC practice).
Adipocytes or bone marrow hematopoietic cells stain strongly.	Both are reported as not detected (HPA tissue IHC); cross reactivity or endogenous detection activity are possible (general IHC practice).	Compare a no primary antibody control and a positive control, then reassess specificity if the unexpected staining remains (general IHC practice).
Diffuse chromogen prevents identification of positive cells.	The result cannot be matched confidently to the reported cell restricted cytoplasmic pattern (HPA tissue IHC).	Review blocking, antibody concentration, washing and detection controls to reduce general IHC background (general IHC practice).
A cerebellar cell shows apparent membrane associated signal.	The HPA cerebellar GLUC annotation includes cytoplasm/membrane staining (HPA tissue IHC); appearance alone is inconclusive.	Identify the stained cell and assess accompanying cytoplasmic staining before deciding whether the pattern is unexpected (HPA tissue IHC; general IHC practice).
Hippocampal staining looks weaker than cerebral cortex staining.	HPA reports medium hippocampal neuronal staining and high cerebral cortex neuronal staining (HPA tissue IHC).	Score each tissue against its own reported level and cell type; use run controls before treating weaker hippocampal signal as assay failure (HPA tissue IHC; general IHC practice).

Source: UniProt P78559 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing MAP1A staining

Immunohistochemical analysis of paraffin-embedded human Colon cancer. 1, Antibody was diluted at 1:200 (4° overnight). 2, Tris-EDTA, pH9.0 was used for antigen retrieval. 3, Secondary antibody was diluted at 1:200 (room temperature, 45min).

A03897 · IHCImmunohistochemical analysis of paraffin-embedded human Colon cancer. 1, Antibody was diluted at 1:200 (4° overnight). 2, Tris-EDTA, pH9.0 w

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000166963-MAP1A/tissue/cerebral+cortex#imid_17891539

HPA · CerebellumHuman Protein Atlas IHC, Cerebellum. Source: https://www.proteinatlas.org/ENSG00000166963-MAP1A/tissue/cerebellum#imid_17891542

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000166963-MAP1A/tissue/colon#imid_17891473

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000166963-MAP1A/tissue/liver#imid_17891458

HPA ICC-IF BJ [Human fibroblast] — MAP1A (HPA066488)

HPA · ICC-IF BJ [Human fibroblast]Human Protein Atlas immunofluorescence, BJ [Human fibroblast], antibody HPA066488; green = MAP1A, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for MAP1A IHC & IF

🧪Run cerebellum first and expect staining in GLUC cells (HPA: High in cerebellar GLUC cells); use adipose tissue as a negative comparator (HPA: Not detected in adipocytes). On the cerebellum slide, assess other cell profiles for background staining, but do not treat them as verified MAP1A-negative cells (HPA: only GLUC cells are specified in the cerebellum row).

Positive control tissue: Cerebellum (GLUC cells - cytoplasm/membrane, HPA High)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show MAP1A in BJ [Human fibroblast], Rh30, U2OS, ASC52telo, Sperm, with annotated localisation: Cytosol (approved) (HPA subcellular).

Technical controls: Include a no-primary, secondary-only control and an isotype control matched to the primary antibody’s host species and clonality; use MAP1A knockout material or a validated immunizing-peptide block as a biological specificity control (standard IHC practice). For chromogenic cerebellar IHC, quench endogenous peroxidase and check for native pigment; if using a biotin-based detection system, control for endogenous biotin (standard IHC practice).

⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A03897 paraffin-section caption does not state a fixative (datasheet: fixative not stated). That caption uses Tris-EDTA at pH 9.0 for retrieval, but does not establish that MAP1A staining depends on that retrieval condition (datasheet: Tris-EDTA pH 9.0); the supplied evidence does not establish that frozen sections or IF are easier. For cerebellar IF, check for neuronal lipofuscin autofluorescence (standard IF practice).

HPA tissue IHC evidence for MAP1A

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Cerebellum	GLUC cells - cytoplasm/membrane	High	Protein (IHC)	HPA →
Cerebral cortex	Neuronal cells	High	Protein (IHC)	HPA →
Bronchus	Ciliated cells (cell body)	Medium	Protein (IHC)	HPA →
Hippocampus	Neuronal cells	Medium	Protein (IHC)	HPA →
Nasopharynx	Ciliated cells (cell body)	Medium	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →
Adrenal gland	Glandular cells	Not detected	Protein (IHC)	HPA →
Appendix	Endocrine cells	Not detected	Protein (IHC)	HPA →
Bone marrow	Hematopoietic cells	Not detected	Protein (IHC)	HPA →
Breast	Adipocytes	Not detected	Protein (IHC)	HPA →

Section 3

Advanced MAP1A IHC Tips

Troubleshoot MAP1A staining in paraffin sections by checking retrieval, cell type, cytoplasmic localisation and appropriate controls before scoring chromogenic signal.

Which retrieval condition should I start with for MAP1A paraffin-section IHC?

Use heat-mediated Tris-EDTA at pH 9.0 for MAP1A antigen retrieval (datasheet A03897). The catalog antibody stained paraffin-embedded human colon cancer after this retrieval, with primary antibody at 1:200 overnight at 4°C (caption A03897). If staining is weak, check that heating and cooling were consistent across sections before adjusting retrieval duration as a controlled trial. Include a known positive neuronal region, such as cerebellum or cerebral cortex, when available (HPA: high MAP1A staining in those tissues). Compare any adjustment against an identically processed section so increased background is not mistaken for improved MAP1A detection.

Could fixation explain weak or uneven MAP1A staining?

The selected image shows paraffin-embedded human colon cancer but does not state its fixative; MAP1A-specific fixation sensitivity is therefore unknown (caption A03897). Record each specimen's fixative and fixation interval, and compare sections processed under the same conditions before attributing signal differences to MAP1A. Keep section thickness, heat retrieval in Tris-EDTA at pH 9.0, and primary incubation at 1:200 overnight at 4°C consistent during that comparison (datasheet A03897; caption A03897). Inspect morphology and tissue adhesion after retrieval, because damaged sections make staining intensity difficult to interpret. Do not infer a fixation effect from MAP1A's cytoskeletal role or its tissue-expression pattern (UniProt P78559 function; HPA tissue IHC).

Where should convincing MAP1A staining appear in tissue sections?

Prioritise cytoplasmic staining in the appropriate cells: MAP1A is a cytoskeletal protein, and the tissue profile describes abundant cytoplasmic expression in neuronal and Purkinje cells (UniProt P78559 subcellular location; HPA tissue IHC). Cerebellum and cerebral cortex provide strong tissue references, whereas hippocampal neuronal staining is reported at a medium level (HPA tissue IHC). MAP1A has no annotated transmembrane segment, so an exclusively crisp cell-surface outline needs independent confirmation (UniProt P78559 topology). Examine signal at high magnification alongside morphology and a counterstain, particularly where closely packed processes obscure cell boundaries. Score the relevant cells separately from adjacent tissue rather than treating every brown structure as MAP1A positive.

How could MAP1A processing or isoforms affect an IHC result?

MAP1A has 2 annotated isoforms and is processed into a heavy chain spanning residues 1–2566 and light chain LC2 spanning 2567–2803 (UniProt P78559 processing; isoforms). Determine which sequence the catalog antibody recognises before interpreting differences between specimens; the supplied caption does not identify its epitope (caption A03897). An epitope in the heavy-chain region and one in LC2 would interrogate different portions of the processed protein (UniProt P78559 processing). MAP1A also has annotated phosphorylation sites, so epitope accessibility may merit investigation if staining changes across preparations (UniProt P78559 modified residues). Do not assign an isoform or phosphorylation state from chromogenic staining alone.

How should I plan an IF comparison with MAP1A IHC?

Use IF as a separate validation experiment: the supplied catalog-antibody evidence describes paraffin-section IHC, while the subcellular resource lists ICC/IF images without establishing that they used this antibody (caption A03897; HPA subcellular). Multiplex MAP1A with a marker identifying the expected neuronal or Purkinje cell population, and compare overlap with the cytoplasmic tissue pattern (HPA tissue IHC). Choose fluorophores after checking tissue autofluorescence and include single-channel controls to assess bleed-through. Plan permeabilisation for an intracellular epitope, since MAP1A is cytoskeletal and lacks a transmembrane segment (UniProt P78559 subcellular location; topology). Confirm the antibody's epitope before interpreting fluorescence outside the expected compartment.

What should I check when MAP1A IHC has diffuse brown background?

First compare the stained section with a no-primary control and inspect whether the deposit follows tissue structures or appears across unrelated cells. MAP1A is reported as cytoplasmic and enriched in brain, so widespread uniform signal in every compartment warrants scrutiny (UniProt P78559 subcellular location; HPA tissue IHC). For peroxidase-based chromogenic detection, check the endogenous peroxidase block, blocking step, washes and DAB development as routine workflow variables. The selected caption reports primary antibody at 1:200 overnight at 4°C and secondary at 1:200 for 45 minutes at room temperature (caption A03897). Change one variable at a time while retaining a positive control.

How can I score MAP1A IHC without confusing cell composition with expression? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell population and compartment before scoring, because the reported MAP1A tissue pattern is strongest in neuronal and Purkinje cells (HPA tissue IHC). For intensity-based scoring, use an H-score: sum each intensity category, 0–3, weighted by its percentage of relevant cells, giving a 0–300 range. Alternatively, report the percentage of positive cells or positive-cell density per mm², with a fixed positivity threshold and consistent region selection. Normalise counts to the number or area of the relevant cell population, and record tissue area and staining batch. Review counterstained morphology so processes, damaged edges and non-target cells do not inflate the score.

How do I distinguish true MAP1A staining from artefact?

Treat cytoplasmic signal in morphologically appropriate neuronal or Purkinje cells as more persuasive than isolated deposit in an unexpected compartment (UniProt P78559 subcellular location; HPA tissue IHC). Compare a positive brain reference and a no-primary control under the same detection conditions; cerebellum and cerebral cortex show high MAP1A staining in the tissue profile (HPA tissue IHC). Examine section edges and necrotic areas for staining that tracks damage rather than intact cells. In peroxidase-based IHC, check whether residual endogenous enzyme activity accounts for brown signal in the control. The colon cancer caption documents staining conditions, but its unspecified fixative and lack of cell-level interpretation do not establish specificity for every brown cell (caption A03897).

Boster reagents

Best MAP1A / Microtubule-associated protein 1A IHC Antibodies

A03897 is listed for MAP1A IHC and IF in human, mouse, and rat (catalog: applications and reactivity); its IHC figure shows a paraffin-embedded human colon cancer section (A03897 image caption).

Real IHC data Immunohistochemical analysis of paraffin-embedded human Colon cancer. 1, Antibody was diluted at 1:200 (4° overnight). 2, Tris-EDTA, pH9.0 was used for antigen retrieval. 3, Secondary antibody was diluted at 1:200 (room temperature, 45min).

Anti-MAP1A Antibody

Cat # A03897

View product →

A03897 has an IHC figure of paraffin-embedded human colon cancer (A03897 image caption). The catalog lists A03897 for IHC and IF in human, mouse, and rat, but supplies no IF figure (catalog: applications, reactivity, IF image alts).

Which to pick: For tissue IHC, choose A03897: its own figure documents a paraffin-embedded section with Tris-EDTA retrieval at pH 9.0 and primary antibody at 1:200 overnight at 4°C; the fixative is unreported (A03897 image caption). For IF, A03897 is listed, but no IF figure or ICC validation is supplied; its host is rabbit and clonality is unspecified (catalog: applications, IF image alts, host, clone). For cross-species work, A03897 lists human, mouse, and rat reactivity (catalog: reactivity).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry P78559 (MAP1A_HUMAN, Microtubule-associated protein 1A).
Human Protein Atlas. MAP1A tissue IHC expression (reliability: Enhanced).
Human Protein Atlas. MAP1A subcellular location (ICC-IF): Mainly localized to the cytosol. In addition localized to the mid piece and principal piece..
Human Protein Atlas. MAP1A antibody validation summary (3 antibodies).
Map-1a regulates Sertoli cell BTB dynamics through the cytoskeletal organization of microtubule and F-actin. Reproductive biology and endocrinology : RB&E 2024 — PMC10988971.
Six stroma-based RNA markers diagnostic for prostate cancer in European-Americans validated at the RNA and protein levels in patients in China. Oncotarget 2015 — PMC4599305.
Tau knockout exacerbates degeneration of parvalbumin-positive neurons in substantia nigra pars reticulata in Parkinson's disease-related α-synuclein A53T mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2020 — PMC8353962.
PubMed PMID:8812494 — UniProt-cited evidence.
PubMed PMID:16572171 — UniProt-cited evidence.
PubMed PMID:7629894 — UniProt-cited evidence.